Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 23INDUSTRY 9NIH 7OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 3Leukemia 3Burkitt Lymphoma 3Solid Tumors 1Solid Tumor 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited 1

Interventions

apatinib 3pembrolizumab 2Poly(ADP-ribose) Polymerase Inhibitors 2Hyperthermic Intraperitoneal Chemotherapy 2Bevacizumab 2taxane 1olaparib 1lenvatinib 1fludarabine 1cediranib 1Whole Genome Sequencing 1Valproic Acid 1Tranexamic Acid 1Tai Ji 1Surgical Procedures, Operative 1Sequence Analysis, RNA 1Saline Solution 1Radiation 1Qigong 1Propranolol 1Positron Emission Tomography Computed Tomography 1Population Groups 1Platinum 1Paclitaxel 1Neoadjuvant Therapy 1Interleukin-2 1Indocyanine Green 1Immunohistochemistry 1Hydralazine 1Gene Expression 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Ovarian Neoplasms × fludarabine × Clear all
NCT03412526 2019-04-04

Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian

Sheba Medical Center

Phase 2 Unknown
15 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡